At Saince, we build the technological foundation that empowers providers to focus entirely on their patients. By seamlessly integrating artificial intelligence, cloud-native infrastructure, and deep system interoperability, we are eliminating inefficiencies and bringing clinical information, radiology, and hospital management into the modern era. We are not just a service provider—we are a high-tech innovation engine for the healthcare industry.

USA: 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
+1 888 472 4623 | sales@saince.com
INDIA: Corporate Address: #6-3-1090, Ground Floor, Block B, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad, Telangana 500082.
Registered Address: #202, Shatabdi Residency, Ramnagargundu, Hyderabad, Telangana 500044.
+91 40 6728 5555 | sales@saince.in
Contact Us
Address 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
Follow Us

Clinical documentation, imaging and intelligence solutions.

Blog Details

Blogs
FDA approves first PSMA PET imaging agent for prostate cancer July 12, 2021

FDA approves first PSMA PET imaging agent for prostate cancer

US FDA approves the Piflufolastat F-18 injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage.

This is a highly effective imaging approach to detect the spread of cancer to other parts of the body.

Read the full article: 

https://www.itnonline.com/content/fda-approves-first-commercially-available-psma-pet-imaging-agent-prostate-cancer